Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 27

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 27
---
 its discretionary authority after a transaction has been completed as Nasdaq typically no longer requires prior review and approval before a modification may occur. A voluntary reduction may expose us to liability or losses if a voluntary reduction is not done in compliance with applicable Nasdaq Listing Rules, which could adversely affect our results of operations, prospects and ultimately the value of our shares of common stock and/or ultimately result in the delisting of shares of our common stock from Nasdaq. Certain Defined Terms: “Adjustment Date” means the close of trading on the 11 thtrading day after the Release Date. “Floor Price” means (i) prior to the Warrant Stockholder Approval, a price equal to the “Nasdaq Minimum Price” on the trading immediately preceding execution of the Purchase Agreements, as defined in Nasdaq Listing Rule 5635(d)(1)(A), or $1.08 per share, or (ii) following approval of the Warrant Stockholder Approval, a price equal to twenty percent (20%) of the Nasdaq Minimum Price on the trading day immediately preceding execution of the Purchase Agreements, as defined in Nasdaq Listing Rule 5635(d)(1)(A), or $0.216 per share. The Floor Price will be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction. “Release Date” means the later of (x) the earlier of (i) the effective date of the registration statement registering all of the securities sold in the Private Placement or (ii) the date that the securities sold in the Private Placement can be sold, assigned or transferred without restriction or limitation pursuant to Rule 144 or Rule 144A promulgated under the Securities Act of 1933 and (y) the date that the Company obtains the Warrant Stockholder Approval. Warrant Stockholder Approval.Under Nasdaq listing rules, the Series A Warrants may not be exercised unless and until we obtain the approval of our stockholders. Pursuant to the terms of the Series A Warrants, we agreed that if we fail to obtain the full Warrant Stockholder Approval we will seek the Warrant Stockholder Approval every 60 days following such a failure (and following any such future failure) until the Warrant Stockholder Approval is obtained. Transferability.Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent. Exchange Listing.We do not intend to apply for the listing of the Warrants on any stock exchange. Without an active